Clinical trial · Observational
Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
LThe main aim of this project is to provide an immunophenotypic and immunometabolic characterisation of patients with Acute Leukaemia, before and after therapy, and to understand how changes in the immune system impact the response to therapy. Specifically: 1. The association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system will be assessed, in order to identify immune-modulatory metabolic mechanisms activated by malignant cells. 2. The association between immunometabolic signatures and response to therapies will be assessed. 3. The role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells will be explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- the association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system, in order to identify immuno-modulatory metabolic mechanisms implemented by malignant cells
- timeFrame
- Once the sample is collected, through study completion, an average of 1 year
- description
- molecular and metabolic characterisation of the bone marrow infiltrate
- measure
- the association between immunometabolic signatures and response to therapies
- timeFrame
- Once the sample is collected, through study completion, an average of 1 year
- description
- evaluation of the immunometabolic profile pre- and post therapy and possible relapse
- measure
- the role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells
- timeFrame
- Once the sample is collected, through study completion, an average of 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: PATIENT * Diagnosis of Acute Leukaemia. * Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies. * age ≥ 18 years. * Signature of informed consent by patients at the time of diagnosis. Healthy donors (AIL BOLOGNA ODV volunteers) * age ≥ 18 years. * Signature of informed consent. Exclusion Criteria: * no one
References
Publications (0)
Data not yet available